Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors

Background and Purpose Orbital and cranial form of idiopathic inflammatory pseudotumors (IIPs) are rare disorders with heterogeneous clinical presentations. Corticosteroids have been the first-line treatment for IIPs, but they are not always effective. Methods We reviewed the medical records of three patients with orbital or cranial form of IIP who were treated with tacrolimus as an adjuvant treatment. Results The three patients showed favorable outcomes with the addition of tacrolimus, which is a calcineurin inhibitor that inhibits T-cell activation and T-cell-dependent B-cell activation. Conclusions Tacrolimus may be a safe and effective immunosuppressant for refractory or relapsing form of orbital or cranial IIPs.

[1]  S. Aaron,et al.  Tolosa–Hunt Syndrome: Long-Term Outcome and Role of Steroid-Sparing Agents , 2020, Annals of Indian Academy of Neurology.

[2]  T. Takeuchi,et al.  Effectiveness of tacrolimus on IgG4-related disease , 2019, Modern rheumatology.

[3]  Bertram G. Katzung,et al.  Basic & Clinical Pharmacology , 2018 .

[4]  Yağmur Seda Yeşiltaş,et al.  Idiopathic Orbital Inflammation: Review of Literature and New Advances , 2018, Middle East African journal of ophthalmology.

[5]  Q. Lu,et al.  Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis , 2018, Lupus Science & Medicine.

[6]  Jyoti,et al.  Tacrolimus: An updated review on delivering strategies for multifarious diseases , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  M. Allez,et al.  Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease , 2017, World journal of hepatology.

[8]  T. Liang,et al.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. , 2017, Gastroenterology.

[9]  F. Bessone,et al.  Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. , 2016, World journal of hepatology.

[10]  J. Porta‐Etessam,et al.  Tolosa-Hunt syndrome with spontaneous remission and recurrence. , 2016, Neurologia.

[11]  J. Thorne,et al.  Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention , 2015, Taiwan journal of ophthalmology.

[12]  R. Perrillo Hepatitis B reactivation from immunosuppressive drug therapy: A global menace , 2015, Clinical liver disease.

[13]  Jianhua Yan,et al.  Idiopathic Orbital Myositis , 2014, The Journal of craniofacial surgery.

[14]  Jacques P. Brown,et al.  A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy , 2013, Allergy, Asthma & Clinical Immunology.

[15]  W. Poon,et al.  Inflammatory pseudotumors of the central nervous system. , 2009, Human pathology.

[16]  B. Schoser Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease – five new cases and review , 2007, Clinical ophthalmology.

[17]  J. Boots Is tacrolimus superior to ciclosporin microemulsion in preventing long-term acute renal transplant rejection? , 2005, Nature Clinical Practice Nephrology.

[18]  N. Reynolds,et al.  Guidelines for prescribing azathioprine in dermatology , 2004, The British journal of dermatology.

[19]  L. Sánchez,et al.  [Idiopathic orbital myositis]. , 1999, Medicina clinica.

[20]  L. Koornneef,et al.  Current status in the treatment of orbital myositis. , 1997, Ophthalmology.

[21]  T. Ferraro,et al.  Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus , 1996, The Lancet.

[22]  J. Sánchez-Román,et al.  Idiopathic orbital myositis: treatment with cyclosporin. , 1993, Annals of the rheumatic diseases.

[23]  F. A. Shamsi,et al.  Orbital Pseudotumor: Distinct Diagnostic Features and Management , 2008, Middle East African journal of ophthalmology.